• LEUKOCARE and Xellia Pharmaceuticals Partner to Discover Innovative Formulations for the Development of Value-added Anti-infective Therapies

    • September 10, 2018
    • Posted By : admin
    • 0 Comment

    LEUKOCARE AG and Xellia Pharmaceuticals, have entered into a global strategic partnership, where both companies will collaborate closely to discover innovative and superior formulations to support the development of Xellia’s pipeline of value-added antibiotic and antifungal products which are intended to enhance patient care.

    Munich-based biotech company LEUKOCARE AG and Xellia Pharmaceuticals, a specialty pharmaceutical company providing important anti-infective treatments against serious and often life threatening infections, today announced a global strategic partnership to discover innovative formulations which will enable the development of value-added anti-infective products intended to enhance patient care.

    Under the agreement, LEUKOCARE will work closely with Xellia’s team of product development experts and apply its proprietary SPS® (Stabilizing and Protecting Solutions) formulation technology platform to discover novel liquid formulations for multiple anti-infective products that will expand Xellia’s portfolio of innovative products. Xellia will have access to LEUKOCARE´s proprietary SPS® formulation technology platform to be used for its antibiotic and antifungal product portfolio. LEUKOCARE will receive annual license fees, formulation development funding, plus royalties on future product sales. Further financial terms of this deal have not been disclosed.

    Aleksandar Danilovski, CSO and Senior Vice President Global R&D and Regulatory Affairs at Xellia, commented: “Having access to LEUKOCARE´s SPS® technologies and formulation development expertise strongly complements our in-house product innovation and development skills and capabilities. This partnership supports our long-term product development strategy of transitioning lyophilized products into liquid formulations. In addition to extending our product offering, liquid formulations will provide improved convenience and ease of use for healthcare professionals and improve patient care. Based on our previous working relationship with LEUKOCARE, we are convinced that our strategic partnership will achieve the desired outcome.”


You Might Also Like

No comments found



error: Content is protected !!